VIR/GILD addendum—I suspect the long delay in starting the phase-2 trial was procedural (i.e. not a lack of interest by the sponsors). Specifically, it may have taken some time to get the FDA’s buy-in on combining the four agents being tested in the trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.